COGENT BIOSCIENCES ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 APEX TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) 56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg...
COGENT BIOSCIENCES ANNOUNCES POSITIVE INITIAL DATA FROM PHASE 2 SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of...
COGENT BIOSCIENCES PRESENTS NEW PRECLINICAL DATA HIGHLIGHTING POTENTIAL BEST-IN-CLASS POTENCY AND SELECTIVITY OF ERBB2 AND PI3KΑ INHIBITOR PROGRAMS AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior...
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program – Overall response rate of 42% and median progression-free survival of 11.1 months in heavily...
Arvinas Announces Oversubscribed $350 Million Private Placement NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at AHA 2023 Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 Data from randomized...
Recent Comments